Citations

Clear

634 citation(s) found for "Hall, A".

Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity
Dragojevic, Sonja , Ryu, Jung Su , Hall, Michael E. , Raucher, Dražen

Mayo Clinic

Molecules | May 25, 2022 | Volume: 27 | Issue: 11 | Pages: 3371

10.3390/molecules27113371 | PMID 35684309 Get It

The anticancer agent doxorubicin(dox) has been widely used in the treatment of a variety of hematological malignancies and solid tumors. Despite doxorubicin’s efficiency in killing tumor cells, severe damage to healthy tissues, along with cardiotoxicity, limits its clinical use. To overcome these adverse side effects, improve patient safety, and enhance therapeutic efficacy, we have designed a thermally responsive biopolymer doxorubicin carrier that can be specifically targeted to tumor tissue by locally applying mild hyperthermia (41 °C). The developed drug vehicle is composed of the following: a cell penetrating peptide (SynB1) to promote tumor and cellular uptake; thermally responsive Elastin-like polypeptide (ELP); and the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-EMCH) containing a pH-sensitive hydrazone linker that releases doxorubicin in the acidic tumor environment. We used the in vivo imaging system, IVIS, to determine biodistribution of doxorubicin-delivered ELP in MDA-MB-231 xenografts in nude mice. Tumor bearing mice were treated with a single IV injection of 10 mg/kg doxorubicin equivalent dose with free doxorubicin, thermally responsive SynB1 ELP 1-DOXO, and a thermally nonresponsive control biopolymer, SynB1 ELP 2-DOXO. Following a 2 h treatment with hyperthermia, tumors showed a 2-fold higher uptake when treated with SynB1 ELP 1-DOXO compared to free doxorubicin. Accumulation of the thermally non-responsive control SynB1 ELP2 –DOXO was comparable to free doxorubicin, indicating that an increase in dox accumulation with ELP is due to aggregation in response to thermal targeting. Higher levels of SynB1 ELP1–DOXO and SynB1 ELP2 –DOXO with respect to free doxorubicin were observed in kidneys. Fluorescence intensity from hearts of animals treated with SynB1 ELP1–DOXO show a 5-fold decrease in accumulation of doxorubicin than the same dose of free doxorubicin. SynB1-ELP1-DOXO biopolymers demonstrated a 6-fold increase in tumor/heart ratio in comparison to free doxorubicin, indicating preferential accumulation of the drug in tumors. These results demonstrate that thermally targeted polymers are a promising therapy to enhance tumor targeting and uptake of anticancer drugs and to minimize free drug toxicity in healthy tissues, representing a great potential for clinical application.
Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
Shah, Meera , Chhetri, Rakchha , Dholakia, Ruchita, Kok, Chung Hoow , Gangat, Naseema , Al‐Kali, Aref , Patnaik, Mrinal M. , Baranwal, Anmol , Greipp, Patricia T. , He, Rong , Begna, Kebede H. , Wei, Andrew H. , Hiwase, Devendra , Shah, Mithun V , Kok, Chung H , Alkhateeb, Hassan B , Patnaik, Mrinal , Baranwal, Anmol , Greipp, Patricia T , He, Rong , Begna, Kebede , Tiong, Ing Soo , Wei, Andrew H , Hiwase, Devendra , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | May 13, 2022 | Volume: 97 | Issue: 8 | Pages: 1013-1022

10.1002/ajh.26589 | PMID 35560061 Get It

AbstractTherapy‐related myeloid neoplasms (t‐MN) are aggressive malignancies in need of effective therapies. The BCL‐2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t‐MN. We retrospectively analyzed 378 t‐MN patients, of which 96 (25.4%, 47 therapy‐related acute myeloid leukemia, 1 therapy‐related chronic myelomonocytic leukemia, 48 therapy‐related myelodysplastic syndrome) received venetoclax. Median interval from t‐MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7–12) months, and patients received a median of 3 (IQR 1–4) cycles. The composite complete remission (CRc) rate, median progression‐free survival (PFS), and overall survival (OS) were 39.1%, 4.9 months, and 7 months, respectively. The upfront use of venetoclax and achieving CRc were associated with improved survival, whereas the presence of Chromosome 7 abnormalities was associated with an inferior survival. Neither the TP53‐status nor the percent bone marrow blast predicted the likelihood of CRc or survival. Paired genetic analysis performed at venetoclax initiation and failure did not show the evidence of the selection of the TP53‐mutated clone. In a propensity‐matched analysis, the use of venetoclax‐based regimen as the first‐line therapy was associated with a superior survival compared to hypomethylating agent (HMA)‐based first‐line therapy (9.4 vs. 6.1 months, p = .01). We conclude that the upfront use of venetoclax with HMA improved survival, though PFS and OS remain poor. As the phenotype at diagnosis or the percent blasts did not predict outcomes, venetoclax should be studied in all t‐MN phenotypes.
Patient and Caregiver-Derived Health Service Improvements for Better Critical Care Recovery
Haines, K.J., Leggett, Nina , Hibbert, Elizabeth , Hall, Tarli, Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Harris, Wendy, Hope, Aluko A. , Jackson, J.C., Johnson, Amanda M. , Kloos, Janet A. , Korzick, Karen , MacTavish, Pamela , Montgomery-Yates, Ashley , Slack, Andrew, Still, M. , Netzer, Giora, Hopkins, RO, Sevin, Carla M. , Boehm, Leanne M. , Eaton, Tammy L. , Meyer, Joel , Quasim, Tara , Wade, Dorothy , Mikkelsen, Mark E. , Iwashyna, Theodore J. , McPeake, Joanne

Mayo Clinic

C94. THE ROAD TO RECOVERY TAKES MANY PATHS: OUTCOMES AFTER CRITICAL ILLNESS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4787-A4787

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4787 Get It

Abstract 9544: Physical Activity in Individuals With Hypertrophic Cardiomyopathy: Baseline Data From the Prospective "Lifestyle and Exercise in Hcm" (live-hcm) Study
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Balaji, Seshadri , Czosek, Richard J. , Bos, Martijn, Choudhury, Lubna , Etheridge, Susan P. , Ware, James S, Maron, Martin S. , Eidem, Benjamin W., Saarel, Elizabeth V. , Maron, Barry J. , Cannom, David S. , Briske, Kaylie A., Simone, Laura, Barth, Cheryl , Concannon, Maryann, Day, Sharlene M. , Salberg, Lisa , Tome, Maite , Ho, Carolyn Y. , James, Cynthia A. , Emery, Michael S. , Cooper, Robert , Geske, Jeffrey B. , Lal, Ashwin K. , Ware, James S. , Dubin, Anne M. , Gray, Belinda , Molossi, Silvana M , Saberi, Sara , Jacoby, Daniel Louis , Harmon, Kimberly G. , Hall, Kevin D. , Olshansky, Brian , Link, Mark S. , Law, Ian H. , Estes, N.A. Mark , Li, Fangyong

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9544 Get It

Introduction: Safety of vigorous exercise for individuals with appropriately-treated HCM remains debated. Physical activity practices in this population have not been described. The objective of this report is to describe physical activity pattern in HCM patients. Long term follow up which is ongoing will determine safety of vigorous exercise. Methods: The NIH-funded LIVE-HCM study prospectively enrolled individuals age 8-60 years with clinically overt HCM or patients with a positive genetic test for sarcomeric HCM. Participants (or parents, for children) answered surveys describing activity patterns. Vigorous exercise was defined as > 6 METS for > 60 hours per year. Clinical and demographic data were derived from medical record review. Results: Among 1798 participants, 745 (41%) reported exercising vigorously, including 296 competitive athletes, with 59 at high-school or college varsity level, 770 (43%) were exercising at moderate, and 283 (16%) at low levels. Of those working, 6% described jobs more active than walking, including 16 in protective services, and 11 in sports/coaching. Clinical/demographic data including imaging characteristics and treatments, are shown in Table, and were mostly similar amongst the exercise-groups. Conclusions: Many patients with HCM are engaged in vigorous exercise including competitive athletics. Prospective follow-up of this cohort is ongoing. Comparison of arrhythmic outcomes outcomes in vigorous exercisers vs moderate/low level exercisers will help determine the safety of exercise in HCM patients.
Jejunal diverticulitis
Woods, Alyn Q., Ly, Justin Q. , Binstock, Aaron J., Beall, Douglas P.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 28-29

10.37549/ar1630 Get It

RCOM RADIOLOGICAL CASE OF THE MONTH
Emery, Robert L., Ly, Justin Q. , Beall, Douglas P. , Jones, Thomas P.

Mayo Clinic

Applied Radiology | April 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: 6-6

10.37549/ar1435 Get It

RCOM RADIOLOGICAL CASE OF THE MONTH
Sullivan, Robert T., Hartman, R. C. , Campbell, Scot E., Q., Ly Justin, Hartman, Robert, Beall, Douglas P.

Mayo Clinic

Applied Radiology | April 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: 32-35

10.37549/ar1345 Get It

RCOM RADIOLOGICAL CASE OF THE MONTH
Waite, Christina, Kendell, Kurtis R., Ly, Justin Q. , Beall, Douglas P.

Mayo Clinic

Applied Radiology | April 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: 34-37

10.37549/ar1305 Get It

RCOM RADIOLOGICAL CASE OF THE MONTH
Levy, Allen J., Wold, Peter B., Ly, Justin Q. , Beall, Douglas P.

Mayo Clinic

Applied Radiology | April 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: 40-45

10.37549/ar1208 Get It

RCOM RADIOLOGICAL CASE OF THE MONTH
L., Emery Robert, Ly, Justin Q. , Frick, Matthew D., Hoffman, Alan D., Beall, Douglas P.

Mayo Clinic

Applied Radiology | April 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: 49-52

10.37549/ar1198 Get It